This method better identifies high-risk patients for atherosclerotic cardiovascular disease (ASCVD).
By reclassifying these patients more accurately, it allows for more personalized, effective treatment plans.
Recent data indicates a steady increase in these prescriptions, with GLP-1 use climbing to 6.6% and SGLT2 to 2.4% among type 1 diabetes patients, showing a significant trend (Ptrend <.001).
This approach marks a significant step forward in targeted cardiovascular care, promising improved outcomes for those at elevated risk. As heart health becomes more data-driven, tools like this are transforming cardiovascular risk prediction.
Source: frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1452869/full